Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.
Zacks·12d ago
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
Zacks·14d ago
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Zacks·20d ago
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD
Bayer's finerenone hits key phase III goal in non-diabetic CKD, paving the way to expand Kerendia???s use as data strengthens its cardiorenal therapy role.
Zacks·28d ago
Bayer Advances Roundup Settlement With Missouri Court Approval
BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.
Zacks·1mo ago
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ahead.
Zacks·1mo ago
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·1mo ago
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
Zacks·1mo ago
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.